Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 6/20 | 0.44 |
| ▸ | ACACA | Q13085 | 5/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2214821 | 0.93 | ACACB (0.43) | ACACBACACAGPR119KCNH2CETP | |
| SCHEMBL13536322 | 0.92 | ACACB (0.42) | ACACBACACAGPR119KCNH2CETP | |
| SCHEMBL2214517 | 0.92 | ACACB (0.42) | ACACBACACAGPR119CETPCHRM2 | |
| SCHEMBL2219354 | 0.92 | ACACB (0.46) | ACACBACACAGPR119NPC1RAB9A | |
| SCHEMBL2217348 | 0.90 | ACACB (0.45) | ACACBACACAGPR119KCNH2NPC1 | |
| SCHEMBL2216040 | 0.89 | GPR119 (0.43) | ACACBACACAGPR119CETPHTR7 | |
| SCHEMBL2215455 | 0.88 | ACACB (0.44) | ACACBACACAGPR119HRH3 | |
| SCHEMBL2216309 | 0.88 | ACACB (0.46) | ACACBACACAGPR119HRH3NPC1 | |
| SCHEMBL2216586 | 0.88 | GPR119 (0.47) | ACACBACACAGPR119KCNH2NPC1 | |
| SCHEMBL2220878 | 0.88 | GPR119 (0.42) | ACACBACACAGPR119CETPCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| WO-2010004348-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | ACACB 2654/4885ACACA 2114/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.